HOUSTON, Sept. 17, 2019 /PRNewswire/ -- Soliton,
Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
that the company has completed its site initiation visit for
the first site to be included in its upcoming keloid scar
proof-of-concept trial. Site initiation visits are for
initial clinical staff training and protocol reviews with the staff
in advance of patient treatments. The company also announced
that patient enrollment for the trial has been completed.
------------------------
Join our more than 200K fans here to
follow the Company: https://soly-investors.com
------------------------
The initial training, site visit and enrollment were completed
at Clear Dermatology & Aesthetic Center in Scottsdale, AZ, by Dr. Brenda LaTowsky, Board Certified Dermatologist.
Site initiation visits at the three additional trial sites will be
conducted over the next six weeks. Patient enrollment has
also been completed.
Dr. Chris Capelli, President, CEO
and co-founder of Soliton, commented, "The completion of these
important steps in the clinical trial process moves Soliton closer
to the treatment of enrolled patients in this fibrotic scar
trial. We look forward to initiating patient treatments in
the very near future."
Keloid and hypertrophic scars represent wound healing gone
awry. A typical example would be a post-surgical scar that
grows beyond its boundaries. Existing published research
suggests that factors relating to the wound-healing environment
(including tension at the boundary of the scar) can cause
fibroblasts to become stuck in a hyper-productive loop, unable to
stop the production of collagen that leads to the thickened, raised
and dense structures often associated with these fibrotic
scars.
The American Osteopathic College of Dermatology estimates that
keloids affect around 10 percent of people,
whereas hypertrophic scars are more common. Keloid
scars are more prevalent among populations with darker
pigmentation. Hypertrophic scars affect men and women
from any racial group equally, although people between
the ages of 10 and 30 years old are more likely to be affected.
Market Research Futures estimates the global market for keloid
and hypertrophic scars may reach $3.9
billion by 2023. There are few treatment options
available for fibrotic scars, which in addition to being
disfiguring, can also cause significant discomfort.
Currently, the most common treatment is the direct injection of
steroids into the scar, however this can require multiple
injections and may not be a permanent solution.
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton is investigating potential additional capabilities of the
RAP technology in preclinical testing, including the potential to
assist existing fat reduction technology in the reduction of fat as
well as improving the appearance of cellulite by creating
mechanical stress at the cellular level and inducing significant
collagen growth.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of the Soliton RAP
device to demonstrate safety and efficacy in the reduction keloid
and hypertrophic scars, the potential for efficacy in fibrotic
scars to extend to other fibrotic disorders, and the ability for
Soliton to receive FDA clearance for these additional
indications. These statements relate to future events, future
expectations, plans and prospects. Although Soliton believes that
the expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under the heading "Item 1A. Risk Factors" in the Form
10-K for year ended December 31, 2018
we filed with the SEC and updated from time to time in our Form
10-Q filings and in our other public filings with the SEC. Any
forward-looking statements contained in this release speak only as
of its date. Soliton undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
CONTACT:
|
Joe Dorame, Joe
Diaz & Robert Blum
|
|
Lytham Partners,
LLC
|
|
602-889-9700
|
|
soly@lythampartners.com
|
View original
content:http://www.prnewswire.com/news-releases/soliton-completes-trial-enrollment-and-conducts-initial-site-training-to-start-keloid-trial-300919289.html
SOURCE Soliton, Inc.